Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study

Background and purposeTo determine the efficacy and feasibility of carbon ion radiotherapy (C-ion RT) for prostate cancer.Patients and methodsBetween April 2000 and November 2003, 175 patients received C-ion RT using a recommended dose fractionation (66.0 GyE/20 fractions) established from prior studies. C-ion RT alone was performed for 33 patients constituting a low-risk group (Stage ⩽ T2a and PSA < 20 ng/ml and Gleason score ⩽ 6); the remaining 142 high-risk patients received an additional androgen deprivation therapy (ADT).ResultsThe 4-year overall survival and bNED rates were 91% and 87%, respectively. Local control was achieved in all but one patient. The 4-year bNED rates were 87% in the low-risk group and 88% in the high-risk group. In very advanced diseases (Stage ⩾ T3a or PSA ⩾20 ng/ml or Gleason score ⩾ 8), there was significant difference in the bNED rate according to period of ADT administration (ADT ⩾ 24 months: 93%, ADT < 24 months: 73%, p < 0.01). Grade 2 late toxicities developed in 4 patients (2%) for the rectum and 9 patients (5%) for the genitourinary system but no Grade 3 or higher toxicity was observed.ConclusionsThe effectiveness of C-ion RT for prostate cancer has been well confirmed. Based on these results, new study of a C-ion RT modified for the administration strategy of ADT according to the patient risk has been started by dividing patients into 3 groups, high-risk, intermediate-risk, and low-risk.